Cytokine IL-6 and IL-10 as Biomarkers in Systemic Lupus Erythematosus

Chun, Hye-Young; Chung, Jae-Wook; Kim, Hyoun‐Ah; Yun, Jeong‐Moon; Jeon, Jun Young; Ye, Young-Min; Kim, Seung Hyun; Park, Hae‐Sim; Suh, Chang‐Hee

doi:10.1007/s10875-007-9104-0

Cited by 326 publications

(286 citation statements)

References 31 publications

Supporting

Mentioning

233

Contrasting

Unclassified

Order By: Relevance

“…The direct regulation of IL-6 by JunB emphasizes IL-6 as a target for anti-cytokine therapy in human SLE patients. IL-6 has been suggested to play a role in the development of SLE (21), and especially in patients with Lupus-nephritis, IL-6 levels are significantly increased (29,30). In addition it was shown that IL-6 can experimentally deteriorate lupus nephritis (7) and that IL-6R blockage can improve it (31).…”

Section: Discussionmentioning

confidence: 99%

“…Anti-histone ABs first occurred at 4-5 months and peaked around 6-12 months of age in JunB ⌬ep mice. Antinuclear SmD Abs, which are also typical for murine and human SLE (21,22), were detected after 5 months. Ablation of IL-6 in JunB ⌬ep IL-6 Ϫ/Ϫ mice could eliminate the systemic autoimmune disease observed in JunB ⌬ep mice and the early mortality observed in JunB ⌬ep IL-6 Ϫ/Ϫ mice (Fig.…”

Section: Sle Phenotype By Junb ⌬Ep and Rescue By Il-6mentioning

confidence: 92%

See 1 more Smart Citation

Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling

Pflegerl

Vesely

Hantusch

et al. 2009

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Sle Phenotype By Junb ⌬Ep and Rescue By Il-6mentioning

confidence: 92%

Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling

Pflegerl

Vesely

Hantusch

et al. 2009

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…Also, the peritoneum is an important site of B cells that produce IL-10 (53), and IL-10 produced by B cells is important in suppressing inflammation in relevant mouse models, with many studies conducted using models of experimental autoimmune encephalitis (EAE) (54,55). Elevated serum levels of IL-10 have been found in SLE patients, and serum IL-10 levels correlate directly with disease severity (56), perhaps reflecting the body's attempts to control systemic inflammation. Whether or not Belimumab leaves the B10 (or interleukin-10 producing B cells) intact has not been determined, but this may come to be important for long-term remission.…”

Section: Introductionmentioning

confidence: 99%

BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus

Fairfax

Mackay

2012

IUBMB Life

View full text Add to dashboard Cite

In November 2009, Human Genome Sciences and Glaxo‐Smith Kline [HGS (Rockville, Maryland) and GSK, respectively] announced that Belimumab, a neutralizing antibody to the tumour necrosis factor (TNF)‐like ligand, B‐cell activating factor (BAFF belonging to the TNF family, also named BLyS), met the primary endpoints in two phase III clinical trials in systemic lupus erythematosus (SLE, lupus). In March 2011, Belimumab was approved by the US Federal Drug Agency for treatment of SLE patients; this was followed in May with approval by the European Medicines Agency for use in the European Union. This is an exciting development as it is the first successful late‐stage clinical trial in SLE in over 40 years. In the light of this breakthrough, we review the key data and research outcomes and examine how blocking BAFF in patients with SLE significantly improves clinical outcomes. © 2012 IUBMB IUBMB Life, 64(7): 595–602, 2012

show abstract

“…16 The disease severity correlates with elevated IL-10 concentrations. 17,18 The serum levels the percentage of alveolar macrophages in BALF (r = 0.39, P = 0.02), FEV 1 (r = 0.43, P = 0.022), and FVC (r = 0.40, P = 0.035). It was negatively correlated with the percentage of lymphocytes in BALF (r = -0.43, P = 0.011).…”

mentioning

confidence: 99%